Amgen Inc. Patent for KRAS G12C Inhibitor Cancer Therapy
Summary
The USPTO has granted Amgen Inc. a patent (US12582657B2) for a combination therapy involving a KRAS G12C inhibitor and other agents for treating cancers. The patent covers pharmaceutical compositions and methods of treatment.
What changed
The United States Patent and Trademark Office (USPTO) has issued patent US12582657B2 to Amgen Inc. This patent covers a combination therapy for cancer treatment that includes a KRAS G12C inhibitor, such as sotorasib or a pharmaceutically acceptable salt thereof, along with one or more additional pharmaceutically active agents. The patent also extends to pharmaceutical compositions containing these agents.
This patent grant represents a new intellectual property right for Amgen concerning a specific cancer treatment modality. While not a regulatory rule imposing obligations on other entities, it signifies a proprietary development in the pharmaceutical sector. Companies involved in oncology research or development, particularly those working with KRAS G12C inhibitors, should be aware of this patent's existence and scope to avoid potential infringement issues.
Archived snapshot
Mar 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
Grant US12582657B2 Kind: B2 Mar 24, 2026
Assignee
Amgen Inc.
Inventors
James Russell Lipford, Jude Robert Canon, Anne Y. Saiki, Karen Louise Rex
Abstract
The present invention provides combination therapy that includes an KRASG12C inhibitor, such as
or a pharmaceutically acceptable salt thereof, and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.
CPC Classifications
A61P 35/00 A61K 45/06 A61K 31/519 A61K 31/506 A61K 31/555 A61K 39/3955 A61K 2300/00 C07K 16/2818
Filing Date
2023-12-19
Application No.
18545953
Claims
30
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.